MeRes-‐1 Dr Ashok Seth

Recommendations

Info

Major Clinical Endpoints • Safety – Primary Endpoint: • MACE at 6-‐months (Cardiac death, MI, ID-‐TLR, ID-‐TVR) – Secondary Endpoints: • Device & procedure success • Scaffold thrombosis (ARC defined) • Efficacy – QCA: Late lumen loss (in-‐scaffold / in-‐segment) – OCT: minimum lumen area (flow area), NIH area – IVUS: Scaffold & lumen area, %VO
Study Leadership • PI – Dr. Ashok Seth, For9s Escorts, New Delhi • Co-‐PI – Dr. Praveen Chandra, Medicity, New Delhi • Co-‐PI – Dr. Vinay K. Bahl, AIIMS, New Delhi • Core Labs – Angiographic – Cardiovascular Research Center, Sao Paulo – IVUS / OCT /MSCT – Cardialysis, RoHerdam • Data Management – CRO – JSS, New Delhi, India
Page 1 and 2: Monday, 31 st October 2016, 12:
Page 3 and 4: Background BRS are now a reali
Page 5 and 6: MeRes100 - BRS Strut Thickness,
Page 7: Key Eligibility Criteria Key In
Page 11 and 12: Baseline Demographics Variable A
Page 13 and 14: Primary Clinical endpoint at 6
Page 15 and 16: QCA Analysis - Angio Subset An
Page 17 and 18: CFD Curve for Late Lumen Loss
Page 19 and 20: Scaffold Implant and Post-‐D
Page 21 and 22: Final Result and Late Follow-
Page 23 and 24: A B C D A B C D MLA: 7.41
Page 25 and 26: CONCLUSIONS • MeRes-‐I tria

MeRes-­‐1 Dr Ashok Seth

Create successful ePaper yourself

Delete template?

Save as template?

MeRes-‐1 Dr Ashok Seth